[
  {
    "ts": null,
    "headline": "Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?",
    "summary": "Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.",
    "url": "https://finnhub.io/api/news?id=a2ddea7070935b5a1f0b44665e291324b43e0d3d7fe2be433d826fafe26307d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758819180,
      "headline": "Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?",
      "id": 136885592,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.",
      "url": "https://finnhub.io/api/news?id=a2ddea7070935b5a1f0b44665e291324b43e0d3d7fe2be433d826fafe26307d5"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?",
    "summary": "AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.",
    "url": "https://finnhub.io/api/news?id=d31d6edd9854fc45e63b74d7037b162c23113955d0eef5fe36364406db0eaaf8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758815520,
      "headline": "AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?",
      "id": 136884808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=d31d6edd9854fc45e63b74d7037b162c23113955d0eef5fe36364406db0eaaf8"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=7b2fdb341cac47f6a4cf2f881e2f64b68d101af8a6cd5831182d68bee5a37215",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758815102,
      "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
      "id": 136885594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=7b2fdb341cac47f6a4cf2f881e2f64b68d101af8a6cd5831182d68bee5a37215"
    }
  },
  {
    "ts": null,
    "headline": "Josh Brown Talks About Johnson & Johnson’s (JNJ) Upcoming ‘Big Catalyst’",
    "summary": "We recently published Wall Street Analysts Like These 10 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks analysts were recently talking about. Josh Brown, CEO of Ritholtz Wealth Management, explained in a latest program on CNBC why he likes Johnson & Johnson (NYSE:JNJ). Brown said the company’s upcoming quarterly report next month could […]",
    "url": "https://finnhub.io/api/news?id=1e38a9db49f1d35097fd6e9c07ca80c4211594465014a44653b9bc68fde3fac4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758808526,
      "headline": "Josh Brown Talks About Johnson & Johnson’s (JNJ) Upcoming ‘Big Catalyst’",
      "id": 136882976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published Wall Street Analysts Like These 10 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks analysts were recently talking about. Josh Brown, CEO of Ritholtz Wealth Management, explained in a latest program on CNBC why he likes Johnson & Johnson (NYSE:JNJ). Brown said the company’s upcoming quarterly report next month could […]",
      "url": "https://finnhub.io/api/news?id=1e38a9db49f1d35097fd6e9c07ca80c4211594465014a44653b9bc68fde3fac4"
    }
  },
  {
    "ts": null,
    "headline": "Hold These 5 ‘Forever Assets’ To Make Money in Your Sleep — Something Buffett Says Is a Must",
    "summary": "Billionaire super-investor Warren Buffett has shared plenty of financial wisdom over his almost 70-year career. When addressing the subject of retirement planning, he famously said, \"If you don't find...",
    "url": "https://finnhub.io/api/news?id=51d297555c2b5c4db82662f2c3d01638077be8cab9677014ebeb23ff4be06cda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758806645,
      "headline": "Hold These 5 ‘Forever Assets’ To Make Money in Your Sleep — Something Buffett Says Is a Must",
      "id": 136885595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Billionaire super-investor Warren Buffett has shared plenty of financial wisdom over his almost 70-year career. When addressing the subject of retirement planning, he famously said, \"If you don't find...",
      "url": "https://finnhub.io/api/news?id=51d297555c2b5c4db82662f2c3d01638077be8cab9677014ebeb23ff4be06cda"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=54051cffbe0d8d60d9aa38f04e49f04ba8e6d0b7efade926efc5a97742450807",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758805205,
      "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
      "id": 136882977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=54051cffbe0d8d60d9aa38f04e49f04ba8e6d0b7efade926efc5a97742450807"
    }
  },
  {
    "ts": null,
    "headline": "Revision Skincare® Appoints Lisa Paley as CEO to Propel the Company’s Next Phase of Growth",
    "summary": "IRVING, Texas, September 25, 2025--Revision Skincare®, a leader in advanced skincare solutions, today announced the appointment of Lisa Paley as CEO.",
    "url": "https://finnhub.io/api/news?id=fb4b830ac6f3f528ea5978036ebd91d3104b398053947f8f82806e04bde65b77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758803400,
      "headline": "Revision Skincare® Appoints Lisa Paley as CEO to Propel the Company’s Next Phase of Growth",
      "id": 136882978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "IRVING, Texas, September 25, 2025--Revision Skincare®, a leader in advanced skincare solutions, today announced the appointment of Lisa Paley as CEO.",
      "url": "https://finnhub.io/api/news?id=fb4b830ac6f3f528ea5978036ebd91d3104b398053947f8f82806e04bde65b77"
    }
  },
  {
    "ts": null,
    "headline": "Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors",
    "summary": "Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Cor",
    "url": "https://finnhub.io/api/news?id=26afe606bf389957c55b2491ecc0237133fb12ce654ed823e68e37e06c7b1cc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758801600,
      "headline": "Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors",
      "id": 136882979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Cor",
      "url": "https://finnhub.io/api/news?id=26afe606bf389957c55b2491ecc0237133fb12ce654ed823e68e37e06c7b1cc9"
    }
  },
  {
    "ts": null,
    "headline": "Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors",
    "summary": "See why Teva Pharmaceutical Industries Limited is shifting the CNS market with Austedo sales growth, new clinical data, and falling debt. Click for my TEVA update.",
    "url": "https://finnhub.io/api/news?id=5654cabe84142939f60002314d296e69ec9908de40922b5433a5fc21b4e997df",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758800565,
      "headline": "Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors",
      "id": 136882693,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196049070/image_2196049070.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "See why Teva Pharmaceutical Industries Limited is shifting the CNS market with Austedo sales growth, new clinical data, and falling debt. Click for my TEVA update.",
      "url": "https://finnhub.io/api/news?id=5654cabe84142939f60002314d296e69ec9908de40922b5433a5fc21b4e997df"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Dow Stocks Are Set to Soar in 2025 and Beyond",
    "summary": "The proverbial planets are aligning for each of their underlying companies.",
    "url": "https://finnhub.io/api/news?id=287e5a91f960ac5e5d280a68c3a11e2cd532e3828f548626a06572f2a9b5a003",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758790320,
      "headline": "These 3 Dow Stocks Are Set to Soar in 2025 and Beyond",
      "id": 136882980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The proverbial planets are aligning for each of their underlying companies.",
      "url": "https://finnhub.io/api/news?id=287e5a91f960ac5e5d280a68c3a11e2cd532e3828f548626a06572f2a9b5a003"
    }
  },
  {
    "ts": null,
    "headline": "3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years",
    "summary": "Not only have these stocks raised their dividends consistently, but they also offer above-average yields.",
    "url": "https://finnhub.io/api/news?id=7f6a169a79660031ca119caab9ddfb8f90a6900ac53e76260e391b128e4cec1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758784500,
      "headline": "3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years",
      "id": 136882981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Not only have these stocks raised their dividends consistently, but they also offer above-average yields.",
      "url": "https://finnhub.io/api/news?id=7f6a169a79660031ca119caab9ddfb8f90a6900ac53e76260e391b128e4cec1d"
    }
  }
]